|
Sign In to gain access to subscriptions and/or personal tools.
|
Ecstasy: Are animal data consistent between species and can they translate to humans?
Neil Easton
Charles A. Marsden
School of Biomedical Science, University of Nottingham, Queen's Medical Centre, Nottingham, UK
The number of 3,4-methylenedioxymethamphetamine (ecstasy or MDMA) animal research articles is rapidly increasing and yet studies which place emphasis on the clinical signi.cance are limited due to a lack of reliable human data. MDMA produces an acute, rapid release of brain serotonin and dopamine in experimental animals and in the rat this is associated with increased locomotor activity and the serotonin behavioural syndrome in rats. MDMA causes dose-dependent hyperthermia, which is potentially fatal, in humans, primates and rodents. Subsequent serotonergic neurotoxicity has been demonstrated by biochemical and histological studies and is reported to last for months in rats and years in non-human primates. Relating human data to .ndings in animals is complicated by reports that MDMA exposure in mice produces selective long-term dopaminergic impairment with no effect on serotonin. This review compares data obtained from animal and human studies and examines the acute physiological, behavioural and biochemical effects of MDMA as well as the long-term behavioural effects together with serotonergic and dopaminergic impairments. Consideration is also given to the role of neurotoxic metabolites and the in.uence of age, sex and user groups on the long-term actions of MDMA.
Key Words: MDMA • ecstasy • metabolite • human • animal • toxicity • behaviour • serotonin • dopamine • age
Journal of Psychopharmacology, Vol. 20, No. 2,
194-210 (2006)
DOI: 10.1177/0269881106061153
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
B. Jones, S. Ben-Hamida, A. Pereira de Vasconcelos, C. Kelche, C. Lazarus, R. Jackisch, and J. Cassel
Effects of ethanol and ecstasy on conditioned place preference in the rat
J Psychopharmacol,
February 1, 2010;
24(2):
275 - 279.
[Abstract]
[PDF]
|
|
|
|
|
|
|
V. Raj, H. Liang, N. Woodward, A. Bauernfeind, J. Lee, M. Dietrich, S. Park, and R. Cowan
MDMA (ecstasy) use is associated with reduced BOLD signal change during semantic recognition in abstinent human polydrug users: a preliminary fMRI study
J Psychopharmacol,
February 1, 2010;
24(2):
187 - 201.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. Rodsiri, A. Green, C. Marsden, and K. Fone
Effect of acute brain tyrosine depletion on MDMA-induced changes in brain 5-HT
J Psychopharmacol,
February 1, 2010;
24(2):
267 - 274.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. Gabrielsson and A. R. Green
Quantitative Pharmacology or Pharmacokinetic Pharmacodynamic Integration Should Be a Vital Component in Integrative Pharmacology
J. Pharmacol. Exp. Ther.,
December 1, 2009;
331(3):
767 - 774.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. E. Schwaninger, M. R. Meyer, J. Zapp, and H. H. Maurer
The Role of Human UDP-Glucuronyltransferases on the Formation of the Methylenedioxymethamphetamine (Ecstasy) Phase II Metabolites R- and S-3-Methoxymethamphetamine 4-O-Glucuronides
Drug Metab. Dispos.,
November 1, 2009;
37(11):
2212 - 2220.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. S. Murnane, N. Murai, L. L. Howell, and W. E. Fantegrossi
Discriminative Stimulus Effects of Psychostimulants and Hallucinogens in S(+)-3,4-Methylenedioxymethamphetamine (MDMA) and R(-)-MDMA Trained Mice
J. Pharmacol. Exp. Ther.,
November 1, 2009;
331(2):
717 - 723.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K Allott, B. Canny, J. Broadbear, N. Stepto, B Murphy, and J Redman
Neuroendocrine and subjective responses to pharmacological challenge with citalopram: a controlled study in male and female ecstasy/MDMA users
J Psychopharmacol,
September 1, 2009;
23(7):
759 - 774.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. R. Meyer, F. T. Peters, and H. H. Maurer
The Role of Human Hepatic Cytochrome P450 Isozymes in the Metabolism of Racemic 3,4-Methylenedioxyethylamphetamine and Its Single Enantiomers
Drug Metab. Dispos.,
June 1, 2009;
37(6):
1152 - 1156.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Selvaraj, R. Hoshi, Z. Bhagwagar, N. V. Murthy, R. Hinz, P. Cowen, H. V. Curran, and P. Grasby
Brain serotonin transporter binding in former users of MDMA ('ecstasy')
The British Journal of Psychiatry,
April 1, 2009;
194(4):
355 - 359.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. R. Meyer, F. T. Peters, and H. H. Maurer
The Role of Human Hepatic Cytochrome P450 Isozymes in the Metabolism of Racemic 3,4-Methylenedioxy-Methamphetamine and Its Enantiomers
Drug Metab. Dispos.,
November 1, 2008;
36(11):
2345 - 2354.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Mueller, F. T. Peters, H. H. Maurer, U. D. McCann, and G. A. Ricaurte
Nonlinear Pharmacokinetics of ({+/-})3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy") and Its Major Metabolites in Squirrel Monkeys at Plasma Concentrations of MDMA That Develop After Typical Psychoactive Doses
J. Pharmacol. Exp. Ther.,
October 1, 2008;
327(1):
38 - 44.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. T. Peters, N. Samyn, T. Kraemer, W. J. Riedel, and H. H. Maurer
Negative-Ion Chemical Ionization Gas Chromatography-Mass Spectrometry Assay for Enantioselective Measurement of Amphetamines in Oral Fluid: Application to a Controlled Study with MDMA and Driving Under the Influence Cases
Clin. Chem.,
April 1, 2007;
53(4):
702 - 710.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. C. Parrott
Ecstasy versus alcohol: Tolstoy and the variations of unhappiness
J Psychopharmacol,
January 1, 2007;
21(1):
3 - 6.
[PDF]
|
|
|
|
|
